Biological Markers Predictive of Invasive Recurrence in DCIS
Author Information
Author(s): Nofech-Mozes Sharon, Spayne Jacqueline, Rakovitch Eileen, Kahn Harriette J, Seth Arun, Pignol Jean-Phillippe, Lickley Lavina, Paszat Lawrence, Hanna Wedad
Primary Institution: Sunnybrook Health Sciences Center
Hypothesis
The study aims to identify novel pathological predictors of invasive recurrence in patients with ductal carcinoma in situ (DCIS).
Conclusion
HER2/neu overexpression is a significant predictor of invasive recurrence in patients with DCIS.
Supporting Evidence
- 41 out of 133 patients recurred, with 21 as invasive recurrence.
- HER2/neu was overexpressed in 45% of cases that recurred as DCIS and 42.9% that recurred as invasive cancer.
- On univariate analysis, HER2/neu overexpression was the only marker associated with an increased risk for any recurrence.
- The hazard ratio for recurrence for HER2/neu positive DCIS was 1.927.
Takeaway
This study found that a specific protein called HER2/neu can help doctors predict if a patient with a certain type of breast cancer will have a recurrence.
Methodology
The study involved a cohort of 133 patients with pure DCIS treated with breast conserving surgery, where various biological markers were analyzed for their association with recurrence.
Limitations
The study is retrospective and may not account for all variables influencing recurrence.
Participant Demographics
Median age at diagnosis was 55 years, with a range from 25 to 85 years.
Statistical Information
P-Value
0.044
Confidence Interval
1.016–3.653
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website